此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

2015年9月11日 更新者:Bristol-Myers Squibb

A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy

The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a and ribavirin can result in higher cure rates in patients who previously failed therapy and may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.

研究概览

研究类型

介入性

注册 (实际的)

512

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Aarhus、丹麦、8200
        • Local Institution
      • Hvidovre、丹麦、2650
        • Local Institution
      • Odense、丹麦、5000
        • Local Institution
    • Alberta
      • Edmonton、Alberta、加拿大、T6G 2B7
        • Local Institution
    • British Columbia
      • Vancouver、British Columbia、加拿大、V6Z 2K5
        • Local Institution
      • Victoria、British Columbia、加拿大、V8V 3P9
        • Local Institution
    • Ontario
      • Toronto、Ontario、加拿大、M5G 2N2
        • Local Institution
      • Toronto、Ontario、加拿大、M5T 2S8
        • Local Institution
    • Jalisco
      • Guadalajara、Jalisco、墨西哥、44160
        • Local Institution
    • Morelos
      • Cuernavaca、Morelos、墨西哥、62170
        • Local Institution
    • Nuevo Leon
      • Monterrey、Nuevo Leon、墨西哥、64710
        • Local Institution
      • Essen、德国、45122
        • Local Institution
      • Frankfurt、德国、60590
        • Local Institution
      • Hamburg、德国、20099
        • Local Institution
      • Hannover、德国、30625
        • Local Institution
      • Cisanello (pisa)、意大利、56124
        • Local Institution
      • Pavia、意大利、27100
        • Local Institution
      • Clichy Cedex、法国、92118
        • Local Institution
      • Creteil Cedex、法国、94010
        • Local Institution
      • Lyon Cedex 04、法国、69317
        • Local Institution
      • Nice Cedex 03、法国、06202
        • Local Institution
      • Paris Cedex、法国、75013
        • Local Institution
      • Paris Cedex 14、法国、75679
        • Local Institution
      • Vandoeuvre Les Nancy、法国、54511
        • Local Institution
      • Ponce、波多黎各、00780
        • Instituto De Investigacion Cientifica Del Sur
      • San Juan、波多黎各、00927
        • Local Institution
    • New South Wales
      • Randwick、New South Wales、澳大利亚、2031
        • Local Institution
    • Victoria
      • Clayton、Victoria、澳大利亚、3168
        • Local Institution
      • Heidelberg、Victoria、澳大利亚、3084
        • Local Institution
      • Prahan、Victoria、澳大利亚、3004
        • Local Institution
    • Western Australia
      • Fremantle、Western Australia、澳大利亚、6160
        • Local Institution
      • Perth、Western Australia、澳大利亚、6001
        • Local Institution
      • Gothenburg、瑞典、SE-416 85
        • Local Institution
      • Stockholm、瑞典、14186
        • Local Institution
    • Alabama
      • Montgomery、Alabama、美国、36116
        • Alabama Liver & Digestive Specialists (Alds)
    • California
      • La Jolla、California、美国、92037
        • Scripps Clinic
      • Los Angeles、California、美国、90048
        • CLI
      • San Diego、California、美国、92114
        • Desta Digestive Disease Medical Center
      • San Francisco、California、美国、94115
        • California Pacific Medical Center
      • San Francisco、California、美国、94110
        • University of California at San Francisco
      • San Francisco、California、美国、94118
        • Kaiser Permanente Medical Center
    • Colorado
      • Aurora、Colorado、美国、80045
        • Transplant Center And Hepatology Clinic, B-154
    • Connecticut
      • New Haven、Connecticut、美国、06520
        • Yale University School Of Medicine
    • Florida
      • Gainesville、Florida、美国、32610-0277
        • University Of Florida Hepatology
      • South Miami、Florida、美国、33143
        • Miami Research Associates
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Indiana University
    • Louisiana
      • New Orleans、Louisiana、美国、70121
        • Ochsner Clinic Foundation
    • Maryland
      • Baltimore、Maryland、美国、21202
        • Mercy Medical Center
      • Baltimore、Maryland、美国、21229
        • Digestive Disease Associates, P.A.
      • Lutherville、Maryland、美国、21093
        • Johns Hopkins Medical Institutions
    • Massachusetts
      • Springfield、Massachusetts、美国、01105
        • The Research Institute
    • Missouri
      • St. Louis、Missouri、美国、63104
        • Saint Louis University
    • New York
      • Albany、New York、美国、12208
        • Samuel S. Stratton Vamc
      • Bronx、New York、美国、10468
        • James J Peters VAMC
      • Great Neck、New York、美国、11201
        • James Sungsik Park, M.D. C.N.S.C.
      • Monticello、New York、美国、12701
        • Upper Delaware Valley Infectious Diseases, Pc
      • Rochester、New York、美国、14642
        • University of Rochester Medical Center
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599-7584
        • University of North Carolina, Chapel Hill
      • Statesville、North Carolina、美国、28677
        • Carolinas Center For Liver Disease
    • Oklahoma
      • Tulsa、Oklahoma、美国、74135
        • Healthcare Research Consultants
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania
    • Rhode Island
      • Providence、Rhode Island、美国、02905
        • University Gastroenterology
    • Tennessee
      • Nashville、Tennessee、美国、37205
        • Nashville Medical Research Institute
    • Texas
      • Arlington、Texas、美国、76012
        • North Texas Research Institute
      • Houston、Texas、美国、77030
        • Liver Associates of Texas
      • Houston、Texas、美国、77030
        • St. Luke'S Episcopal Hospital - Baylor College Of Medicine
      • San Antonio、Texas、美国、78215
        • Alamo Medical Research
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Metropolitan Research
    • Wisconsin
      • Madison、Wisconsin、美国、53715
        • Dean Clinic
    • Buenos Aires
      • Ciudad De Buenos Aires、Buenos Aires、阿根廷、C1121ABE
        • Local Institution
      • Ciudad De Buenos Aires、Buenos Aires、阿根廷、C1181ACH
        • Local Institution
    • Santa Fe
      • Prov De Santa Fe、Santa Fe、阿根廷、2000
        • Local Institution

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Subjects chronically infected with HCV genotype 1
  • Non-responder to prior therapy with peginterferon alfa and ribavirin
  • HCV RNA viral load of 100,00 IU/mL
  • Results of a liver biopsy ≤ 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study population)
  • Ultrasound, CT scan or MRI results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma
  • Body Mass Index (BMI) of 18 to 35 kg/m2

Exclusion Criteria:

  • Positive for Hepatitis B infection (HBsAg) or HIV-1/HIV-2 antibody at screening
  • Evidence of medical condition associated with chronic liver disease other than HCV
  • Evidence of decompensated cirrhosis based on radiologic criteria or biopsy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin
(prior null responders)
Film coated tablet, Oral, 20 mg, once daily, 24 weeks
Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
其他名称:
  • 派罗欣®
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
其他名称:
  • 科佩格斯®
实验性的:Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin
(prior null responders)
Film coated tablet, Oral, 20 mg, once daily, 24 weeks
Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
其他名称:
  • 派罗欣®
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
其他名称:
  • 科佩格斯®
实验性的:Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin
(prior partial responders)
Film coated tablet, Oral, 20 mg, once daily, 24 weeks
Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
其他名称:
  • 派罗欣®
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
其他名称:
  • 科佩格斯®
实验性的:Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin
(prior partial responders)
Film coated tablet, Oral, 20 mg, once daily, 24 weeks
Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
其他名称:
  • 派罗欣®
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
其他名称:
  • 科佩格斯®
实验性的:Arm 5: Placebo plus peginterferon alfa-2a and ribavirin
(prior partial responders only)
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
其他名称:
  • 派罗欣®
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
其他名称:
  • 科佩格斯®
Film coated tablet, Oral, 0mg, Once daily, 24 weeks

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants With Extended Rapid Virologic Response (eRVR)
大体时间:Week 4, Week 12
eRVR was defined as undetectable Hepatitis C virus RNA at both Weeks 4 and 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.
Week 4, Week 12
Percentage of Participants With 24-week Sustained Virologic Response (SVR24)
大体时间:Follow-up Week 24
SVR24 was defined as undetectable RNA (Hepatitis C Virus [HCV] RNA <lower limit of quantitation [LLOQ], target not detected [TND]) at follow-up Week 24. TND was 10 IU/mL. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.
Follow-up Week 24
Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment
大体时间:From first dose to last dose plus 7 days, up to 49 weeks
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity; or was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.
From first dose to last dose plus 7 days, up to 49 weeks
Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period
大体时间:From day 8 post last dose of treatment up-to Week 72
AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.
From day 8 post last dose of treatment up-to Week 72

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants With Rapid Virologic Response (RVR)
大体时间:Week 4
RVR was defined as undetectable RNA ie., Hepatitis C virus (HCV) RNA <lower limit of quantitation [LLOQ], target not detected (TND) at Week 4. TND was 10 IU/mL. HCV RNA levels were measured by the Roche Cobas® TaqMan® HCV Test version 2.0 from the central laboratory.
Week 4
Percentage of Participants With Complete Early Virologic Response (cEVR)
大体时间:Week 12
cEVR was defined as undetectable RNA ie., Hepatitis C virus (HCV) RNA <lower limit of quantitation [LLOQ], target not detected (TND) at Week 12. TND was 10 IU/mL. HCV RNA levels were measured by the Roche Cobas® TaqMan® HCV Test version 2.0 from the central laboratory.
Week 12
Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)
大体时间:Follow-up Week 12
SVR12 was defined as undetectable RNA ie., Hepatitis C virus (HCV) RNA <lower limit of quantitation (LLOQ), target not detected (TND) at follow-up Week 12. TND was 10 IU/mL. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.
Follow-up Week 12
Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
大体时间:Baseline to follow-up Week 48
Non-structural protein 5A of HCV resistance associated polymorphism in GT-1a samples included M28L/T/V, Q30H, L31M, H54Y, H58C/D/N/P/Q, E62D and Y93C.
Baseline to follow-up Week 48
Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
大体时间:Baseline to follow-up Week 48
Non-structural protein 5A of HCV resistance associated polymorphisms in GT-1b samples, included L28M/V, R30H/Q, L31M, Q54H/N/Y, P58A/Q/S, Q62E/K/N/R/S, A92T/V and Y93F/H.
Baseline to follow-up Week 48

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年8月1日

初级完成 (实际的)

2012年6月1日

研究完成 (实际的)

2012年12月1日

研究注册日期

首次提交

2010年7月16日

首先提交符合 QC 标准的

2010年7月26日

首次发布 (估计)

2010年7月28日

研究记录更新

最后更新发布 (估计)

2015年10月12日

上次提交的符合 QC 标准的更新

2015年9月11日

最后验证

2015年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅